Skip to content
Open access

Genomic Profiling, Risk Stratification, and Post-Transformation Treatment Outcomes in Patients with Transformed Small-Cell Lung Cancer: A Multicenter Analysis.

Aug 2026 · Lung Cancer · Vol 220, pp. 109566 · 0 citations · 25 references
Medicine

TL;DR

Age, RB1/NTRK1 mutation, and secondary T790M mutation were identified as independent risk factors and integrated into a predictive model with high accuracy and establish a clinically applicable model for early prediction and risk stratification of SCLC transformation.

Abstract

Background

Transformed small-cell lung cancer (T-SCLC) is an increasingly recognized resistance mechanism in EGFR-mutant lung adenocarcinoma. This study aimed to identify early predictors of histologic transformation and evaluate post-transformation treatment outcomes.

Methods

We retrospectively collected 163 T-SCLC patients from five Chinese centers. Next-generation sequencing was performed on 60 EGFR-mutant patients, including 47 paired primary-transformed samples. Integrated genomic and clinical analyses were conducted to delineate molecular features and survival outcomes.

Results

Among 150 EGFR-mutant patients, the median time to SCLC transformation was 25.8 months and median post-transformation overall survival (OS) was 14.2 months. Clinical and survival data for the 13 EGFR wild-type patients are reported descriptively given the limited sample size. Among 108 treatment-evaluable patients, first-line EGFR-TKI plus chemotherapy, chemotherapy alone, and immune checkpoint inhibitors (ICIs) plus chemotherapy yielded median progression-free survival (PFS) of 6.2, 5.30, and 4.07 months (P = 0.041) and median OS of 21.2, 27.6, and 13.6 months (P = 0.193). In later-line therapy, taxane-based regimens achieved a median PFS of 6.93 months, outperforming camptothecin-based (1.13 months) and other regimens (1.90 months; P = 0.049). High evolutionary diversity was associated with shorter post-transformation OS (6.77 vs. 11.10 months), with restricted cubic spline analysis showing a nonsignificant trend toward a nonlinear association (P = 0.055).Age, RB1/NTRK1 mutation, and secondary T790M mutation were identified as independent risk factors and integrated into a predictive model with high accuracy.

Conclusions

This study establishes a clinically applicable model for early prediction and risk stratification of SCLC transformation. Taxane-based regimens emerge as a promising later-line therapeutic option for T-SCLC.

Read PDF

Similar papers

Open access Oct 2026

Real-World Treatment Outcomes and Prognostic Factors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer: A Single-Center Study from a High-Volume Tertiary Chest Hospital

The survival outcomes observed in this cohort were generally consistent with previously published real-world data in EGFR-mutant metastatic NSCLC, and ECOG performance status and bone metastasis were significantly associated with OS, while associations involving histopathological subtype and uncommon EGFR mutations sho...

A. Koçanoğlu, O. Ünsal, F. Kuş et al. · 0 citations
Open access Oct 2026

Overall survival prediction and risk stratification for advanced EGFR-mutant lung adenocarcinoma patients treated with first-line tyrosine kinase inhibitors

Lung adenocarcinoma (LAD) is the most common non-small cell lung cancer subtype, with frequent epidermal growth factor receptor (EGFR) mutations in Asians. First-line tyrosine kinase inhibitors (TKIs) improves survival but resistance is inevitable, leading to disease progression and even death. We aimed to develo...

Wen-Jian Tang, Jia-Wei Feng, Yuan Kang et al. · 0 citations
Nov 2026

Characteristics and outcomes of patients with advanced or metastatic non-small cell lung cancer harboring a HER2-activating mutation: a real-world retrospective cohort study using a US clinico-genomic database.

INTRODUCTION Human epidermal growth factor receptor 2 (HER2/ERBB2) mutated non-small cell lung cancer (NSCLC) is associated with poor prognosis and limited treatment options. METHODS This retrospective cohort study used electronic health records from US academic and community cancer centers to describe characteristic...

Xiu-Ning Le, C. Chouaid, F. López-Ríos et al. · 0 citations
Open access Nov 2026

Osimertinib, platinum, and etoposide for patients with metastatic EGFR/TP53/RB1-mutant lung cancers at risk for histological transformation.

Although EGFR inhibitors are highly effective for treating EGFR-mutant lung adenocarcinomas (EGFR+ LUADs), resistance inevitably emerges, with histologic transformation to small cell lung cancer (SCLC) representing a particularly aggressive mechanism. Our prospective trial enrolled patients with EGFR+ LUAD at high risk...

L. Morrill Gavarró, Monica F. Chen, Á. Quintanal-Villalonga et al. · 0 citations
Open access Oct 2026

Broad genomic profiling, targeted therapy receipt, and overall survival among patients with metastatic non-squamous non-small cell lung cancer.

51 Background: Broad genomic profiling (BGP) is recommended for all patients with metastatic non-squamous NSCLC to guide targeted therapy (TT) selection. As actionable alterations and matched therapies continue to expand, BGP may identify a broader group of patients eligible for TT and consequently improve pati...

Si-Da Huang, John Rothen, Jessica B. Long et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.